"Changing the gut to change Parkinson’s: Faecal Microbiota Transplantation (FMT)" by Dr Arnout Bruggeman.
The gut microbiome has become an increasingly important area of Parkinson’s research. Scientists are investigating the complex relationship between the gut, the brain and the immune system, and whether changes in the gut microbiome may contribute to Parkinson’s or influence how the disease develops.
One of the most intriguing approaches being investigated is Faecal Microbiota Transplantation (FMT), the transfer of gut bacteria from a healthy donor to the gut of another person.
In this webinar, Dr Arnout Bruggeman will explain what we currently know about the gut-brain axis in Parkinson’s and what the research into FMT is telling us.
Among the questions we will explore:
What is the gut-brain axis, and why it matters in Parkinson’s?
What changes have researchers observed in the gut microbiome of people with Parkinson’s?
What exactly is faecal microbiota transplantation, and how might it work?
What have clinical trials of FMT in Parkinson’s shown so far?
What are the limitations and unanswered questions?
Could FMT eventually become part of the treatment landscape for Parkinson’s?
Join us to hear directly from a neurologist and researcher working at the forefront of this fascinating area of Parkinson’s research, and to put your questions directly to Dr Bruggeman during the live Q&A.
---
About Dr Arnout Bruggeman
Dr Arnout Bruggeman is a movement disorders neurologist at Ghent University Hospital, Belgium. His clinical work includes deep brain stimulation, infusion therapies, botulinum toxin injections and electrophysiological studies in movement disorders.
His research focuses on clinical movement disorders and the gut-brain axis, particularly in Parkinson’s disease. He founded the Ghent Biobank for Movement Disorders, which collects longitudinal clinical data and biological samples, and collaborates with research groups at Ghent University and VIB, the Flemish Institute for Biotechnology, on gut-brain axis research.
His PhD research culminated in a clinical trial investigating the effects of faecal microbiota transplantation in people with Parkinson’s.